AGMB

AgomAb Therapeutics NV ADR

9.03

Oct 07 • 10:51 AM ET +0.19 (2.15%)

Healthcare Biotechnology Belgium Small NASD

Peers: INCY KYMR BMRN CRNX RYTM VKTX KRYS AXSM MDGL NBIX

Index	-
Market Cap	444.73M
Enterprise Value	157.94M
Income	-
Sales	-
Book/sh	6.16
Cash/sh	5.85
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	62
IPO	Feb 06, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.47
P/C	1.54
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.88
Current Ratio	12.88
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.09
EPS next Q	-0.37
EPS this Y	98.90%
EPS next Y	-17.49%
EPS next 5Y	76.03%
EPS past 3/5Y	-102.05% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-177.84% -

Insider Own	25.98%
Insider Trans	0.24%
Inst Own	26.72%
Inst Trans	0.09%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-17.06%
SMA50	-28.82%
SMA200	-27.53%
Trades

Shs Outstand	48.74M
Shs Float	36.45M
Short Float	2.38%
Short Ratio	6.43
Short Interest	0.87M
52W High	17.82 -49.33%
52W Low	7.97 13.30%
Volatility	14.50% 10.69%
ATR (14)	1.06
RSI (14)	33.29
Beta	-
Rel Volume	1.00
Avg Volume	135.03K
Volume	33,886

Perf Week	-18.65%
Perf Month	-39.44%
Perf Quarter	-30.70%
Perf Half Y	-8.32%
Perf YTD	-38.57%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	37.73
Prev Close	8.84
Price	9.03
Change %	2.15%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-25-26	Initiated	Piper Sandler	Overweight	$60
Aug-19-26	Initiated	Cantor Fitzgerald	Overweight
Jul-23-26	Initiated	B. Riley Securities	Buy	$34
Jun-22-26	Initiated	H.C. Wainwright	Buy	$35
Mar-03-26	Initiated	Morgan Stanley	Overweight	$28
Mar-03-26	Initiated	Leerink Partners	Outperform	$36
Mar-03-26	Initiated	JP Morgan	Overweight	$32

Oct-01-26 09:27AM	Agomab stock jumps on positive trial data (Investing.com) -22.07%
06:30AM	Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease (GlobeNewswire)
Sep-14-26 04:05PM	Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study (GlobeNewswire) -5.97%
Sep-11-26 04:05PM	Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors (GlobeNewswire) -6.31%
Sep-03-26 04:05PM	Agomab to Participate in Upcoming Investor Conferences (GlobeNewswire) +8.57% +6.41%
04:07PM	Loading…
Aug-10-26 04:07PM	Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors (GlobeNewswire)
Aug-06-26 04:01PM	Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook (GlobeNewswire) -5.73% +7.41%
Jun-23-26 04:05PM	Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease (GlobeNewswire) +6.20%
May-27-26 05:00AM	Agomab Announces Results of Annual General Meeting (GlobeNewswire) +5.61%
May-14-26 07:30AM	Agomab to Participate in Upcoming Conferences (GlobeNewswire)
Apr-23-26 06:14PM	Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook (GlobeNewswire)
Mar-26-26 07:00AM	Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire) -7.70%
Feb-09-26 04:05PM	Agomab Announces Closing of Initial Public Offering (GlobeNewswire) +6.55%
Feb-07-26 10:55AM	Agomab indicated to open at $15.50, IPO priced at $16 (TipRanks)
Feb-05-26 07:24PM	Agomab Announces Pricing of Initial Public Offering (GlobeNewswire)

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

Ph.D.Dr. Tim Knotnerus MSc

FounderMr. Paolo Michieli Ph.D.

Chief Financial OfficerMr. Pierre Kemula B.Sc.

Vice President of Investor RelationsSofie Van Gijsel

General CounselMs. Ellen Lefever

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Epstein David R	Director	Oct 06 '26	Buy	8.70	5,000	43,500	10,000	Oct 07 08:57 AM
Epstein David R	Director	Oct 05 '26	Buy	8.57	5,000	42,850	5,000	Oct 07 08:57 AM
Kemula Pierre Thadee Victor	Chief Financial Officer	Oct 06 '26	Buy	8.59	10,000	85,940	10,000	Oct 07 08:47 AM
Knotnerus Tim Jasper	Chief Executive Officer	Oct 05 '26	Buy	8.48	6,000	50,880	16,823	Oct 07 08:06 AM
Knotnerus Tim Jasper	Chief Executive Officer	Oct 06 '26	Buy	8.70	5,000	43,500	21,823	Oct 07 08:06 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGMB

AgomAb Therapeutics NV ADR

Upgrade your Finviz experience